Estradiol-treated mesenchymal stem cells improve myocardial recovery after ischemia

dc.contributor.authorErwin, Graham S.
dc.contributor.authorCrisostomo, Paul R.
dc.contributor.authorWang, Yue
dc.contributor.authorWang, Meijing
dc.contributor.authorMarkel, Troy A.
dc.contributor.authorGuzman, Mike
dc.contributor.authorSando, Ian C.
dc.contributor.authorSharma, Rahul
dc.contributor.authorMeldrum, Daniel R.
dc.contributor.departmentSurgery, School of Medicineen_US
dc.date.accessioned2020-01-06T14:46:35Z
dc.date.available2020-01-06T14:46:35Z
dc.date.issued2009-04
dc.description.abstractBACKGROUND: Stem cell therapy is a promising treatment modality for injured cardiac tissue. A novel mechanism for this cardioprotection may include paracrine actions. Our lab has recently shown that gender differences exist in mesenchymal stem cell (MSC) paracrine function. Estrogen is implicated in the cardioprotection found in females. It remains unknown whether 17beta-estradiol (E2) affects MSC paracrine function and whether E2-treated MSCs may better protect injured cardiac tissue. We hypothesize that E2-exposed MSCs infused into hearts prior to ischemia may demonstrate increased vascular endothelial growth factor (VEGF) production and greater protection of myocardial function compared to untreated MSCs. MATERIALS AND METHODS: Untreated and E2-treated MSCs were isolated, cultured, and plated and supernatants were harvested for VEGF assay (enzyme-linked immunosorbent assay). Adult male Sprague-Dawley rat hearts (n = 13) were isolated and perfused via Langendorff model and subjected to 15 min equilibration, 25 min warm global ischemia, and 40 min reperfusion. Hearts were randomly assigned to perfusate vehicle, untreated male MSC, or E2-treated male MSC. Transcoronary delivery of 1 million MSCs was performed immediately prior to ischemia in experimental hearts. RESULTS: E2-treated MSCs provoked significantly more VEGF production than untreated MSCs (933.2 +/- 64.9 versus 595.8 +/- 10.7 pg/mL). Postischemic recovery of left ventricular developed pressure was significantly greater in hearts infused with E2-treated MSCs (66.9 +/- 3.3%) than untreated MSCs (48.7 +/- 3.7%) and vehicle (28.9 +/- 4.6%) at end reperfusion. There was also greater recovery of the end diastolic pressure with E2-treated MSCs than untreated MSCs and vehicle. CONCLUSIONS: Preischemic infusion of MSCs protects myocardial function and viability. E2-treated MSCs may enhance this paracrine protection, which suggests that ex vivo modification of MSCs may improve therapeutic outcome.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationErwin, G. S., Crisostomo, P. R., Wang, Y., Wang, M., Markel, T. A., Guzman, M., … Meldrum, D. R. (2009). Estradiol-treated mesenchymal stem cells improve myocardial recovery after ischemia. The Journal of surgical research, 152(2), 319–324. doi:10.1016/j.jss.2008.02.006en_US
dc.identifier.urihttps://hdl.handle.net/1805/21739
dc.language.isoen_USen_US
dc.publisherElsevieren_US
dc.relation.isversionof10.1016/j.jss.2008.02.006en_US
dc.relation.journalJournal of Surgical Researchen_US
dc.rightsPublisher Policyen_US
dc.sourcePMCen_US
dc.subjectSex hormonesen_US
dc.subjectCardioprotectionen_US
dc.subjectEstrogenen_US
dc.subjectParacrineen_US
dc.subjectVEGFen_US
dc.titleEstradiol-treated mesenchymal stem cells improve myocardial recovery after ischemiaen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
nihms-104295.pdf
Size:
874.39 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: